1. McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017). Anthracycline chemotherapy and cardiotoxicity. Cardiovascular Drugs and Therapy, 31, 63–75.
2. Rahman, A. M., Yusuf, S. W., & Ewer, M. S. (2007). Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. International Journal of Nanomedicine, 2, 567.
3. Volkova, M., & Russell, R. (2011). Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Current Cardiology Reviews, 7, 214–220.
4. de Oliveira Silva, J., Miranda, S. E. M., Leite, E. A., de Paula Sabino, A., Borges, K. B. G., Cardoso, V. N., Cassali, G. D., Guimarães, A. G., Oliveira, M. C., & de Barros, A. L. B. (2018). Toxicological study of a new doxorubicin-loaded pH-sensitive liposome: A preclinical approach. Toxicology and Applied Pharmacology, 352, 162–169
5. Renu, K., Abilash, V., Pichiah, P. T., & Arunachalam, S. (2017). Molecular mechanism of doxorubicin-induced cardiomyopathy: An update. European Journal of Pharmacology, 818, 241–253